Skip to content

Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery

Prospective Randomized Monocentric Trial of Mechanical Bowel Preparation Alone vs Mechanical Bowel Preparation Combined With Oral Antibiotics Before Colorectal Resections for Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03563586
Acronym
MECCA
Enrollment
210
Registered
2018-06-20
Start date
2018-04-01
Completion date
2021-06-01
Last updated
2020-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic, Bowel Cancer, Colorectal Cancer, Surgical Site Infection

Keywords

oral antibiotic, mechanical bowel preparation, colorectal cancer, surgical site infection

Brief summary

Investigation of the role of adding oral antibiotics to preoperative mechanical bowel preparation before colorectal surgery for cancer.

Detailed description

The aim of the study is to investigate whether the addition of oral antibiotics to Mechanical Bowel Preparation (MBP) prior to colorectal cancer surgical procedures reduce the superfical and deep surgical site (SSI) infectious complications. The study is prospective and is designed in a randomized single-blinded controlled fashion. It is taking place at one academic surgical unit of Athens Medical School, located at a tertiary referal institution. Patients scheduled to undergo an elective surgical resection for colon or rectal cancer will be allocated to either formal MBP the day before surgery or a combined MBP with administration of oral antibiotics. Exclusion criteria are the following: emergency surgery, obstructive or perforated cancer, patients intolerance to bowel preparation regimen and allergies to orally administered antibiotics. Intervention arms: Patients will be randomised into two groups, concealed from the treating surgeon. Group A: Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with MBP (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) Group B: MBP (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours. Outcome measures: The primary end point is surgical site infection (SSI), including (i) superficial wound infection, (ii) deep wound infection, and (iii) intrabdominal infection (contaminated fluid or pus collection) within 30 days of the procedure (decrease 3% in the rate) Secondary measures: Anastomotic leaks, other surgical and non-surgical compliactions, hospital length of stay, readmission rate, patients' preparation tolerance, preparation regimens side-effects, time to beginning of adjuvant treatment for colorectal cancer. Sample Size: It is estimated that 105 patients per treatment arm are needed.

Interventions

OTHERBowel Preparation plus antibiotics

Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)

OTHERBowel Preparation

Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours

Sponsors

National and Kapodistrian University of Athens
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Scheduled colorectal cancer surgery

Exclusion criteria

* Emergency surgery * Obstructive and perforated cancer * Intolerance to bowel preparation regimen * Allergies to orally administered antibiotics

Design outcomes

Primary

MeasureTime frameDescription
Surgical Site Infections30 daysSurgical Site Infections

Secondary

MeasureTime frameDescription
Other surgical and non-surgical compliactions30 daysOther surgical and non-surgical compliactions
Hospital length of stay30 daysHospital length of stay
Readmission rate30 daysReadmission rate
Anastomotic leaks30 daysAnastomotic leaks
Preparation regimens side-effects30 daysPreparation regimens side-effects
Time to beginning of adjuvant treatment for colorectal cancer60 daysTime to beginning of adjuvant treatment for colorectal cancer
Patients' preparation tolerance30 daysPatients' preparation tolerance

Countries

Greece

Contacts

Primary ContactGeorge Theodoropoulos
georgetheocrs@live.com+306945463593
Backup ContactGeorgia Georgiou
georgia_cy@hotmail.com+306945292510

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026